Curaleaf Price Target Spikes, Fueled By German Cannabis Legalization Changes — ROTH MKM Explains
Strategic Outlook And Earnings Forecast
According to ROTH MKM, a privately held investment banking company, cannabis multi-state operator Curaleaf Holdings, Inc. (CSE: CURA) (OTC: CURLF) is poised to unveil its fourth-quarter earnings for 2023 on March 6, with projections indicating a modest rise in revenue and EBITDA.
This anticipated growth is credited to Curaleaf’s strategic positioning in essential markets such as Maryland and New Jersey and improved cost management.
Nevertheless, challenges like price competition and underused facilities are expected to moderate these improvements.
The company has forecasted a slight sequential growth in revenue, aiming for better margins and cash flows through focused operational execution and consolidation activities.
Revenue And Earnings Expectations
ROTH MKM estimates Curaleaf’s revenue will reach $334.5 million, reflecting a steady year-over-year increase. This forecast is slightly below the consensus expectation of $337.7 million.
The adjusted EBITDA is predicted at $77.9 million, showcasing a decline from the previous year but surpassing consensus estimates of $73.9 million. Curaleaf’s strategic market leadership in Maryland and New Jersey is anticipated to counterbalance the impacts of seasonal promotions and wholesale price reductions.
With Germany’s recent move towards cannabis …
Full story available on Benzinga.com